Sernova Biotherapeutics Inc. (OTCMKTS:SEOVF) Sees Large Decline in Short Interest

Sernova Biotherapeutics Inc. (OTCMKTS:SEOVF) was the target of a significant decline in short interest in June. As of June 15th, there was short interest totaling 130,922 shares, a decline of 35.0% from the May 31st total of 201,477 shares. Currently, 0.0% of the shares of the stock are short sold. Based on an average daily volume of 48,613 shares, the short-interest ratio is currently 2.7 days.

Sernova Biotherapeutics Stock Up 3.6%

SEOVF opened at $0.10 on Thursday. The company has a market cap of $39.12 million, a PE ratio of -2.59 and a beta of 0.82. Sernova Biotherapeutics has a twelve month low of $0.07 and a twelve month high of $0.16. The company has a 50-day moving average price of $0.11 and a 200 day moving average price of $0.11.

Sernova Biotherapeutics (OTCMKTS:SEOVF) last posted its quarterly earnings data on Thursday, June 11th. The company reported ($0.01) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.01).

Sernova Biotherapeutics Company Profile

Sernova Biotherapeutics is a clinical‐stage biotechnology company focused on developing and commercializing cell‐based therapeutic technologies for patients with chronic and life‐threatening diseases. Headquartered in London, Ontario, Canada, the firm is advancing an implantable device platform designed to support the long-term survival and function of therapeutic cells. The company’s lead product candidate, known as the Cell Pouch System, is engineered to create a vascularized environment in which transplanted cells can thrive, with an initial emphasis on treating patients with type 1 diabetes.

In its core program, Sernova has initiated a Phase I/II clinical trial evaluating the safety and efficacy of the Cell Pouch System in individuals with type 1 diabetes who require islet cell transplantation.